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Effect of Interferon Therapy on the Development of Hepatocellular Carcinoma in Liver Cirrhosis 
Patients with Hepatitis C Virus Infection 
Koji Kakihara1）, Satoshi Mochida1）, Kunihiko Ohnishi2）, Kenji Fujiwara1）( 1）Third Department of Internal Medicine, 
Saitama Medical School Moroyama, Iruma-gun, Saitama 350-0495, Japan,2）Ohnishi Clinic, Tsurugashima-shi, 
Saitama 350 -2202, Japan)
Interferon (IFN) has been widely used as an useful antiviral agent for HCV-related chronic hepatitis patients to 
block the development to cirrhosis which often complicates hepatocellular carcinoma (HCC). However, its efficacy 
for cirrhotic patients is still equivocal. In 63 patients with HCV-related cirrhotic patients, the effect of IFN therapy 
on the occurrence of HCC was evaluated. The patients were allocated into IFN-therapy group and control group 
according to patients’ will. IFN-α or IFN-β was basically administered for 6 months or 6 weeks at various doses. 
There was no difference in demographic and clinical features between both groups. HCC occurred in 6 of 39 
patients (15%) in the IFN-therapy group during the observation period (IFN group ; 44.0±5.3 months, Control 
group ; 42.4±5.0 months) but in 9 of 24 patients (38%) in the control group (p＜0.05). The survival rate was also 
significantly improved in the IFN-therapy group. There were 7 of the 39 IFN-therapy group patients who showed 
sustained normal levels of serum GPT activity and no detectable HCV-RNA, but none of the control group patients 
(p＜0.05). In these patients of the IFN-therapy group, serum albumin levels and platelet and WBC counts were 
significantly higher at the end of the observation period than before the IFN therapy, but such increases were 
not seen in the IFN-therapy group patients who did not show normalization in serum GPT activity and HCV-RNA. 
Cox’s multi-variate regression analysis revealed that alcohol intake, serum HCV-RNA levels and IFN therapy 
were significant factors related to the HCC occurrence in both groups. There were two patients who developed 
complications associated with the IFN therapy, but completely reversed after its discontinuation. In conclusion, 
IFN therapy may be an advisable candidate for HCV-related cirrhotic patients whose serum HCV-RNA levels were 
rather low to block the occurrence of HCC.
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Table 1. Demographic and Clinical Features in IFN and 
Control Groups
Table 2. Laboratory Tests before IFN Treatment and at the 
End of Observation in IFN and Control Groups
Table 3. The Number of Patients in which Serum HCV-RNA 
Disappeared during the Follow-up Period
Table 4. Demographic and Clinical Features of Complete 
Responders (CR) and Non-Responders (NR) in IFN Group
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RNA量 (p＝ 0.02)及び IFN療法の有無（p＝ 0.05）が，
独立した有意な要因として抽出された．それぞれのリ
スク比は，飲酒家は非飲酒家に対して 4.1，血清 HCV-




































Table 5. Laboratory Tests before Treatment and at the 
End of Observation in Complete Responders (CR) and Non-
Responders (NR) in IFN Group
Table 6. Incidence of Hepatocellular Carcinoma (HCC) in 
Complete Responders (CR) and Non-Responders (NR) in IFN 
and Control Groups
Table 7. Factors affecting the Development of Hepatocellular 
Carcinoma in Liver Cirrhosis Patients with Hepatitis C Virus 
Infection
Cox’s multi-variate regression analysis was performed using 
factors classifi ed as follows ; sex (male : female), age (60 
years old or more : less than 60),  history of blood transfusion 
(none : exist), history of alcohol intake (none : exist), Child-
Pugh score (6 or more : 5 or less), serum HCV-RNA level (107





































































Fig. 1. Incidence of Hepatocellular carcinoma (HCC) and Survival Rate in Complete Responders (CR) and Non Responders 
(NR) in IFN group and in Control Group.
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